Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Levallorphan | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Levallorphan | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Levallorphan | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Levallorphan | hsa00190 | Oxidative phosphorylation | 1.03E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Levallorphan | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Levallorphan | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | Levallorphan | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | Levallorphan | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Levallorphan | hsa00565 | Ether lipid metabolism | 3.00E-03 | 1 | Q8N661 | TMEM86B | More | | Levallorphan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Levallorphan | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Levallorphan | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | | Levallorphan | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Levallorphan | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Levallorphan | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Levallorphan | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Levallorphan | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.94E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Levallorphan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Levallorphan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Levallorphan | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Levallorphan | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | | Levallorphan | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Levallorphan | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Levallorphan | hsa03008 | Ribosome biogenesis in eukaryotes | 2.03E-03 | 5 | Q9NYH9, O14980, O60832, P78345, Q9BVP2 | UTP6, XPO1, DKC1, RPP38, GNL3 | More | | Levallorphan | hsa03010 | Ribosome | 1.03E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | | Levallorphan | hsa03013 | RNA transport | 1.40E-08 | 17 | O14980, P52298, Q09161, O14893, P61326, P38919, P37198, Q7Z3B4, P35658, Q14152, P55884, O75822, P78345, Q14240, P23588, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, EIF4A3, NUP62, NUP54, NUP214, EIF3A, EIF3B, EIF3J, RPP38, EIF4A2, EIF4B, TACC3, FXR1 | More | | Levallorphan | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Levallorphan | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Levallorphan | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | | Levallorphan | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Levallorphan | hsa04010 | MAPK signaling pathway | 1.23E-03 | 3 | P08069, Q9H2K8, Q12933 | IGF1R, TAOK3, TRAF2 | More | | Levallorphan | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04015 | Rap1 signaling pathway | 5.18E-04 | 3 | P08069, P06213, O00522 | IGF1R, INSR, KRIT1 | More | | Levallorphan | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Levallorphan | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Levallorphan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.70E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | Levallorphan | hsa04062 | Chemokine signaling pathway | 6.08E-06 | 15 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, GSK3B | More | | Levallorphan | hsa04064 | NF-kappa B signaling pathway | 1.13E-05 | 19 | P10415, Q13489, P51617, O00463, Q13546, P14778, P29965, P19174, Q04759, Q9UDY8, Q13077, P07948, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, IRAK1, TRAF5, RIPK1, IL1R1, CD40LG, PLCG1, PRKCQ, MALT1, TRAF1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Levallorphan | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04070 | Phosphatidylinositol signaling system | 3.54E-03 | 5 | P0DP23, Q14643, P23743, O14732, P17252 | CALM1, ITPR1, DGKA, IMPA2, PRKCA | More | | Levallorphan | hsa04071 | Sphingolipid signaling pathway | 2.48E-06 | 11 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q12933, Q02156 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, TRAF2, PRKCE | More | | Levallorphan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Levallorphan | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Levallorphan | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Levallorphan | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04120 | Ubiquitin mediated proteolysis | 2.51E-03 | 6 | Q14145, Q13042, P62837, Q15751, O95071, P0CG47 | KEAP1, CDC16, UBE2D2, HERC1, UBR5, UBB | More | | Levallorphan | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Levallorphan | hsa04137 | Mitophagy - animal | 9.52E-03 | 2 | Q07817, P0CG47 | BCL2L1, UBB | More | | Levallorphan | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04142 | Lysosome | 3.31E-02 | 3 | P43234, Q9UBR2, P34059 | CTSO, CTSZ, GALNS | More | | Levallorphan | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | | Levallorphan | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | | Levallorphan | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04151 | PI3K-Akt signaling pathway | 1.65E-03 | 16 | P62753, P25116, O43521, P27348, P49767, Q13362, Q8WYR1, P62873, P16144, O60603, P01568, P18848, P10415, P17252, O00141, Q6ZUJ8 | RPS6, F2R, BCL2L11, YWHAQ, VEGFC, PPP2R5C, PIK3R5, GNB1, ITGB4, TLR2, IFNA21, ATF4, BCL2, PRKCA, SGK, PIK3AP1 | More | | Levallorphan | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04210 | Apoptosis | 3.63E-02 | 3 | O75460, O43521, P18848 | ERN1, BCL2L11, ATF4 | More | | Levallorphan | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04213 | Longevity regulating pathway - multiple species | 1.14E-03 | 5 | P42338, P08069, Q9Y4H2, P11142, Q13547 | PIK3CB, IGF1R, IRS2, HSPA8, HDAC1 | More | | Levallorphan | hsa04217 | Necroptosis | 1.79E-07 | 18 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q99878, Q93077, P10415, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, HIST1H2AC, BCL2, CHMP4B, CHMP2A, PPID | More | | Levallorphan | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Levallorphan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.45E-04 | 10 | P09493, P07550, P22694, P18848, Q13362, Q16537, P0DP23, P17252, P10415, P20020 | TPM1, ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | Levallorphan | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Levallorphan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Levallorphan | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Levallorphan | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Levallorphan | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Levallorphan | hsa04612 | Antigen processing and presentation | 5.80E-06 | 10 | P13765, P48382, P01730, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Levallorphan | hsa04613 | Neutrophil extracellular trap formation | 5.01E-07 | 20 | P17252, P11215, O60603, P08246, Q13547, Q92769, P04908, Q6FI13, Q93077, P58876, P62807, P33778, Q16778, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, ELA2, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, H2BC3, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | | Levallorphan | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Levallorphan | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | Levallorphan | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Levallorphan | hsa04630 | JAK-STAT signaling pathway | 1.44E-02 | 4 | P01106, Q09472, P48551, P16871 | MYC, EP300, IFNAR2, IL7R | More | | Levallorphan | hsa04640 | Hematopoietic cell lineage | 9.84E-08 | 15 | P13612, P21926, P14778, P27930, P11215, P20023, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P16871, P13765 | ITGA4, CD9, IL1R1, IL1R2, ITGAM, CR2, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, IL7R, HLA-DOB | More | | Levallorphan | hsa04650 | Natural killer cell mediated cytotoxicity | 3.13E-11 | 14 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Levallorphan | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Levallorphan | hsa04658 | Th1 and Th2 cell differentiation | 2.82E-10 | 12 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Levallorphan | hsa04659 | Th17 cell differentiation | 2.90E-08 | 12 | Q04759, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Levallorphan | hsa04660 | T cell receptor signaling pathway | 1.05E-07 | 15 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Levallorphan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Levallorphan | hsa04668 | TNF signaling pathway | 2.67E-03 | 6 | P01375, P18848, P19875, P01584, P14780, P20333 | TNF, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B | More | | Levallorphan | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Levallorphan | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | Levallorphan | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Levallorphan | hsa04720 | Long-term potentiation | 3.85E-03 | 3 | P17252, P0DP23, Q14643 | PRKCA, CALM1, ITPR1 | More | | Levallorphan | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Levallorphan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Levallorphan | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | Levallorphan | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | Levallorphan | hsa04728 | Dopaminergic synapse | 2.76E-03 | 11 | Q14643, P17252, P14416, P62873, P63218, P50151, P49841, Q16539, P49407, Q13362, P0DP23 | ITPR1, PRKCA, DRD2, GNB1, GNG5, GNG10, GSK3B, MAPK14, ARRB1, PPP2R5C, CALM1 | More | | Levallorphan | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Levallorphan | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Levallorphan | hsa04912 | GnRH signaling pathway | 3.85E-03 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Levallorphan | hsa04913 | Ovarian steroidogenesis | 5.67E-04 | 4 | P42330, P22694, P06213, P08069 | AKR1C3, PRKACB, INSR, IGF1R | More | | Levallorphan | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa04919 | Thyroid hormone signaling pathway | 4.44E-02 | 3 | P60709, Q09472, P01106 | ACTB, EP300, MYC | More | | Levallorphan | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | Levallorphan | hsa04923 | Regulation of lipolysis in adipocytes | 4.24E-03 | 4 | P07550, P06213, P42338, Q9Y4H2 | ADRB2, INSR, PIK3CB, IRS2 | More | | Levallorphan | hsa04924 | Renin secretion | 7.38E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | Levallorphan | hsa04925 | Aldosterone synthesis and secretion | 1.54E-02 | 4 | Q14643, P0DP23, P17252, P20020 | ITPR1, CALM1, PRKCA, ATP2B1 | More | | Levallorphan | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Levallorphan | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Levallorphan | hsa04930 | Type II diabetes mellitus | 1.28E-03 | 2 | P06213, Q02156 | INSR, PRKCE | More | | Levallorphan | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | | Levallorphan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.27E-02 | 5 | P42224, P10415, Q12778, P49767, P17252 | STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | | Levallorphan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Levallorphan | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | | Levallorphan | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Levallorphan | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Levallorphan | hsa04966 | Collecting duct acid secretion | 1.13E-04 | 4 | Q13488, P02730, P00918, Q9Y666 | TCIRG1, SLC4A1, CA2, SLC12A7 | More | | Levallorphan | hsa04970 | Salivary secretion | 4.79E-04 | 7 | P07550, P22694, Q14643, P20020, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, PRKCA, CALM1, CAMP | More | | Levallorphan | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Levallorphan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Levallorphan | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | Levallorphan | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Levallorphan | hsa05010 | Alzheimer disease | 5.01E-03 | 13 | Q16718, O14521, P13073, Q14643, O75460, P0DP23, P0DP24, P01584, P18848, Q13509, P68371, P05141, Q08752 | NDUFA5, SDHD, COX4I1, ITPR1, ERN1, CALM1, CALM2, IL1B, ATF4, TUBB3, TUBB2C, SLC25A5, PPID | More | | Levallorphan | hsa05012 | Parkinson disease | 4.51E-03 | 11 | Q16718, O14521, P13073, P05141, O75460, P18848, Q14643, P0DP23, P0DP24, Q13509, P68371 | NDUFA5, SDHD, COX4I1, SLC25A5, ERN1, ATF4, ITPR1, CALM1, CALM2, TUBB3, TUBB2C | More | | Levallorphan | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Levallorphan | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | Levallorphan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.05E-05 | 19 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P17252, P20333, Q16539, P01584, Q08752, P0DP23, P0DP24 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, PRKCA, TNFRSF1B, MAPK14, IL1B, PPID, CALM1, CALM2 | More | | Levallorphan | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Levallorphan | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Levallorphan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.62E-04 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Levallorphan | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | Levallorphan | hsa05132 | Salmonella infection | 4.24E-05 | 12 | P51617, Q9UJU2, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Levallorphan | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Levallorphan | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Levallorphan | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Levallorphan | hsa05140 | Leishmaniasis | 5.36E-06 | 9 | P14598, P42224, P13765, O60603, P25963, P29350, P49006, P51617, Q15080 | NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, PTPN6, MARCKSL1, IRAK1, NCF4 | More | | Levallorphan | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Levallorphan | hsa05144 | Malaria | 1.30E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Levallorphan | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | Levallorphan | hsa05146 | Amoebiasis | 7.67E-07 | 12 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Levallorphan | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | Levallorphan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Levallorphan | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Levallorphan | hsa05164 | Influenza A | 8.62E-03 | 4 | Q09472, P48551, P29728, P60709 | EP300, IFNAR2, OAS2, ACTB | More | | Levallorphan | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | Levallorphan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.73E-02 | 6 | P01568, P42224, P62873, Q14643, P0DP23, Q9UJU2 | IFNA21, STAT1, GNB1, ITPR1, CALM1, LEF1 | More | | Levallorphan | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Levallorphan | hsa05169 | Epstein-Barr virus infection | 2.78E-05 | 19 | P20023, P13765, P01106, Q13547, Q92769, P04637, Q13546, O00463, P10415, P07948, Q13761, P24522, P48551, O60603, P29728, P51617, P07766, P09693, P20963 | CR2, HLA-DOB, MYC, HDAC1, HDAC2, TP53, RIPK1, TRAF5, BCL2, LYN, RUNX3, GADD45A, IFNAR2, TLR2, OAS2, IRAK1, CD3E, CD3G, CD247 | More | | Levallorphan | hsa05170 | Human immunodeficiency virus 1 infection | 1.03E-04 | 12 | P62873, P0DP23, P17252, Q13546, Q14643, P01568, P51617, O60603, Q13315, P09693, P10415, Q9Y6Q5 | GNB1, CALM1, PRKCA, RIPK1, ITPR1, IFNA21, IRAK1, TLR2, ATM, CD3G, BCL2, AP1M2 | More | | Levallorphan | hsa05171 | Coronavirus disease - COVID-19 | 1.93E-02 | 4 | P48551, P29728, P46777, P50914 | IFNAR2, OAS2, RPL5, RPL14 | More | | Levallorphan | hsa05200 | Pathways in cancer | 4.99E-02 | 12 | P42224, Q9UJU2, P17252, P14923, P10415, Q13489, P49767, Q12778, P25116, P62873, P0DP23, P01568 | STAT1, LEF1, PRKCA, JUP, BCL2, BIRC3, VEGFC, FOXO1, F2R, GNB1, CALM1, IFNA21 | More | | Levallorphan | hsa05202 | Transcriptional misregulation in cancer | 8.55E-04 | 5 | P27930, P11215, P08069, Q13547, P12980 | IL1R2, ITGAM, IGF1R, HDAC1, LYL1 | More | | Levallorphan | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Levallorphan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Levallorphan | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | Levallorphan | hsa05211 | Renal cell carcinoma | 1.67E-02 | 2 | Q09472, Q99814 | EP300, EPAS1 | More | | Levallorphan | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Levallorphan | hsa05214 | Glioma | 1.40E-03 | 5 | P08069, P0DP23, P17252, P04637, P24522 | IGF1R, CALM1, PRKCA, TP53, GADD45A | More | | Levallorphan | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa05216 | Thyroid cancer | 1.58E-03 | 5 | P01106, Q9UJU2, P04637, P24522, O75293 | MYC, LEF1, TP53, GADD45A, GADD45B | More | | Levallorphan | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Levallorphan | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Levallorphan | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Levallorphan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.97E-06 | 9 | P42338, P19174, P07766, P20963, P09693, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ, EML4, CD4 | More | | Levallorphan | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Levallorphan | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Levallorphan | hsa05322 | Systemic lupus erythematosus | 2.33E-07 | 12 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Levallorphan | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | Levallorphan | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | Levallorphan | hsa05332 | Graft-versus-host disease | 9.47E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Levallorphan | hsa05340 | Primary immunodeficiency | 1.31E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | | Levallorphan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Levallorphan | hsa05415 | Diabetic cardiomyopathy | 5.60E-05 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | Levallorphan | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | Levallorphan | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |